and the severe disease dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Most dengue infections are asymptomatic or cause mild symptoms, which are characterized by undifferentiated fever ...

The World Health Organization, which had been campaigning for vaccines to treat Dengue is reviewing the data. It has now recommended that Dengvaxia should only be given to previously infected ...

Sanofi's Dengvaxia is the first-ever approved dengue vaccine. In addition to the Philippines, the company said the vaccine was registered in Argentina, Australia, Bangladesh, Bolivia, Brazil ...

While many infections are mild, the disease can progress to severe forms, such as dengue hemorrhagic fever or dengue shock syndrome ... The dengue vaccine, Dengvaxia™, is an option for ...

Sanofi’s is to pay back money to the Philippines government for unused doses of its Dengue fever vaccine, after serious safety concerns halted its use. Dengvaxia is the first vaccine of its kind ...

The controversy reportedly began in 2017 with reports that the dengue vaccine Dengvaxia could trigger severe symptoms in individuals who had not been previously infected with the dengue virus.